Literature DB >> 17257908

Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study.

Isabelle Durieu1, Evelyne Vericel, Daniel Guichardant, Hubert Roth, Jean-Paul Steghens, Jocelyne Drai, Raphaele Nove Josserand, Eric Fontaine, Michel Lagarde, Gabriel Bellon.   

Abstract

BACKGROUND: An imbalance in the ratio of arachidonic acid and docosahexaenoic acid (DHA) was found in cystic fibrosis (CF) affected tissues and was suggested to promote inflammation. Several studies have shown that the long chain n-3 fatty acids reduced inflammatory activity while others have highlighted prooxidant activity of DHA at high concentrations. The aim of our study was to evaluate the effects of an intravenous fish-oil emulsion enriched with n-3 FA in patients with CF on plasma and platelet FA composition and peroxidation markers.
METHODS: 13 patients with CF received one IV emulsion per week of 2 mL/kg fish-oil n-3 emulsion for 12 weeks.
RESULTS: There was a significant increase in 20:5 n-3 and 22:6 n-3 platelet FA composition, no variation in 20:4 n-6, a decrease in n-9. There was no variation in plasma FA composition. Specific urinary markers of lipid peroxidation derived from n-3 and n-6 showed a very high level before infusion compared with usual values in healthy subjects which was not affected by treatment. A significant weight loss and a decrease in reduced glutathione were observed in adult patients.
CONCLUSIONS: The intravenous administration of n-3 FA in CF patients induced a significant modification in platelet FA composition but no modification of oxidative markers. However, the weight loss and the decreased level in reduced glutathione observed in adult patients may suggest a potential deleterious activity for some patients. Further studies are necessary to determine the optimal dose and route for long chain FA administration required to reach a potential beneficial effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257908     DOI: 10.1016/j.jcf.2006.12.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  4 in total

1.  CFTR depletion results in changes in fatty acid composition and promotes lipogenesis in intestinal Caco 2/15 cells.

Authors:  Geneviève Mailhot; Rémi Rabasa-Lhoret; Alain Moreau; Yves Berthiaume; Emile Levy
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

2.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

3.  Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

Review 4.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.